A subscription to JoVE is required to view this content. Sign in or start your free trial.
The present protocol describes a unique, clinically relevant model of peripheral arterial disease that combines femoral artery and vein electrocoagulation with the administration of a nitric oxide synthase inhibitor to induce hindlimb gangrene in FVB mice. Intracardiac DiI perfusion is then used for high-resolution, three-dimensional imaging of the footpad vasculature.
Peripheral arterial disease (PAD) is a significant cause of morbidity resulting from chronic exposure to atherosclerotic risk factors. Patients suffering from its most severe form, chronic limb-threatening ischemia (CLTI), face substantial impairments to daily living, including chronic pain, limited walking distance without pain, and nonhealing wounds. Preclinical models have been developed in various animals to study PAD, but mouse hindlimb ischemia remains the most widely used. There can be significant variation in response to ischemic insult in these models depending on the mouse strain used and the site, number, and means of arterial disruption. This protocol describes a unique method combining femoral artery and vein electrocoagulation with the administration of a nitric oxide synthase (NOS) inhibitor to reliably induce footpad gangrene in Friend Virus B (FVB) mice that resembles the tissue loss of CLTI. While traditional means of assessing reperfusion such as laser Doppler perfusion imaging (LDPI) are still recommended, intracardiac perfusion of the lipophilic dye 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) is used to label the vasculature. Subsequent whole-mount confocal laser scanning microscopy allows for high-resolution, three-dimensional (3D) reconstruction of footpad vascular networks that complements traditional means of assessing reperfusion in hindlimb ischemia models.
Peripheral arterial disease (PAD), characterized by reduced blood flow to the extremities due to atherosclerosis, affects 6.5 million people in the United States and 200 million people worldwide1. Patients with PAD experience reduced limb function and quality of life, and those with CLTI, the most severe form of PAD, are at increased risk for amputation and death with a 5-year mortality rate nearing 50%2. In clinical practice, patients with ankle-brachial indices (ABI) <0.9 are considered to have PAD, and those with ABI <0.4 associated with either rest pain or tissue loss as having CLTI3. ....
All animal experiments described in the protocol were approved by the University of Miami Institutional Animal Care and Use Committee (IACUC). FVB mice, both male and female, aged 8-12 weeks, were used for the study.
1. Preparation of L-NAME solution
This protocol details a reliable means of inducing ischemia and tissue loss in the murine footpad using a combination of femoral artery and vein coagulation with L-NAME administration, a nitric oxide synthase inhibitor, in susceptible FVB mice. Figure 1 details the anatomy of the murine hindlimb vasculature and indicates the sites of the femoral artery and vein coagulation (yellow X), just proximal to the lateral circumflex femoral artery (LCFA) and proximal to the saphenopopliteal junction........
While mouse hindlimb ischemia is the most widely used preclinical model to study neovascularization in PAD and CLTI, there is significant variation in ischemia severity and recovery depending on the specific mouse strain used and the site, number, and method of arterial disruption. The combination of femoral artery ligation and IP administration of L-NAME can reliably induce hindlimb gangrene in FVB mice11. The same treatment results in hindlimb ischemia without tissue loss in C57BL/6 mice, wherea.......
This work was supported by grants to Z-J L and OC V from the National Institutes of Health [R01HL149452 and VITA (NHLBl-CSB-HV-2017-01-JS)]. We also thank the Microscopy and Imaging Facility of the Miami Project to Cure Paralysis at the University of Miami School of Medicine for providing access to their image analysis and processing software.
....Name | Company | Catalog Number | Comments |
Binder clips (small) | Office supply store | ||
Buprenorphine (sustained-release) | |||
Butterfly needle (25 G with Luer-Lok) | VWR | 10148-584 | |
Confocal laser scanning microscope | Leica | TCS SP5 | |
DiI (1,1'-Dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) | Invitrogen | D282 | |
Electrocautery device | Gemini Cautery System | 5917 | |
Ethanol (100%) | VWR | 89370-084 | |
Fiji (ImageJ) software | NIH | Used version 2.1.0. Free download, no license required. | |
Foam biopsy pads | Fisher Scientific | 22-038-221 | |
Formalin (neutral buffered, 10%) | VWR | 89370-094 | |
FVB mice | Jackson Laboratory | 001800 | |
Glucose | Sigma-Aldrich | G7528 | Used version 2.1.0. |
HCl (1 M) | Sigma-Aldrich | 13-1700 | |
Imaris software | Oxford Instruments | Used version 9.6.0. | |
Isoflurane | Pivetal | NDC 46066-755-04 | |
KCl | Sigma-Aldrich | P9333 | |
Ketamine | |||
L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride) | Sigma-Aldrich | N5751 | |
Laser Doppler perfusion imager | MoorLDI | moorLDI2-HIR | Used moorLDI V5 software. |
Microscope slides (25 x 75 x 1 mm) | VWR | 48311-703 | |
Na2HPO4 | Sigma-Aldrich | S7907 | |
NaCl | Sigma-Aldrich | S7653 | |
NaH2PO4 | Sigma-Aldrich | S8282 | |
NaOH | Sigma-Aldrich | S8263 | |
Needles (27 G) | BD | 305109 | |
Povidone-iodine swabstick (10%) | Medline | MDS093901ZZ | |
Surgical instruments | Roboz Surgical | Fine forceps, needle driver, spring scissors, and hemostat are recommended. | |
Suture (5-0 absorbable) | DemeTECH | G275017B0P | |
Syringes (10 mL) | BD | 305482 | |
Three-way stopcocks | Cole-Parmer | 19406-49 | |
Vascular Analysis Plugin | Free download, no license required. See reference: Elfarnawany (2015). | ||
Xylazine |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved